Replies to post #157522 on Biotech Values

[DewDiligence]

Are you saying XOMA has to hit on 2 of the 3 Phase 3 trials for approval? So, positive results in Eyeguard B won't be sufficient for approval if the two prior trials fail beforehand?

It’s not written in stone, but it’s very likely that two successes among the three Eyeguard studies will be necessary for FDA approval. This is XOMA’s own take on the situation.